We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
HCG (Human Chorionic Gonadotropin)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most HCG (Human Chorionic Gonadotropin) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2005–2023 with a typical study size of 51 participants.
Based on 7 studies · 1 meta-analysis · 1 RCT · 1,844 total participants
Confidence
ModerateBy outcome
HCG (Human Chorionic Gonadotropin) has an evidence score of 5.5/10 — emerging evidence based on 7 indexed studies, including 1 meta-analysis. A placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism, and for maintaining intratesticular testosterone and sperm production in men on testosterone therapy who want to preserve fertility. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks. Representative study: PMID 37466846.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Notable regimens that report including HCG (Human Chorionic Gonadotropin) — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
HCG (Human Chorionic Gonadotropin) — LH-mimetic gonadotropin
A placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism, and for maintaining intratesticular testosterone and sperm production in men on testosterone therapy who want to preserve fertility. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks.
hCG has solid, trial-backed roles on the gonadal axis — a randomized dose-response showing it maintains intratesticular testosterone under TRT, established spermatogenesis induction in hypogonadotropic men, and meta-analysis-level use as the female ovulation trigger — but the TRT-fertility-adjunct use rests on small cohorts, the male-fertility evidence is largely observational, and none of it extends beyond the gonadal axis (no longevity/healthspan benefit), with real OHSS/estradiol risks and grey-market sourcing concerns.
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by the placenta whose beta-subunit closely resembles luteinizing hormone (LH).
It binds and activates the LH/CG receptor (LHCGR) on testicular Leydig cells in men and ovarian theca/granulosa cells in women, where it acts as a long-acting LH analogue — its much longer circulating half-life than native LH is exactly why it is therapeutically useful.
It is a prescription drug (urinary-derived as Pregnyl/Novarel, or recombinant choriogonadotropin alfa as Ovidrel/r-hCG), not a dietary supplement. The human evidence clusters around three well-validated, gonadal-axis uses.
First, female fertility: hCG is the standard agent to trigger final oocyte maturation and ovulation in induction and assisted-reproduction (IVF/IUI) cycles, where a single dose mimics the natural mid-cycle LH surge — recombinant and urinary hCG produce comparable outcomes, and hCG remains the reference 'trigger' against which newer dual-trigger protocols are compared.
Second, male fertility induction: in men with hypogonadotropic hypogonadism, hCG stimulates Leydig-cell testosterone production and (alone in post-pubertally acquired/adult-onset cases with adequate testicular volume, or combined with FSH in congenital cases such as Kallmann syndrome) induces spermatogenesis, with success predicted by baseline testicular volume, inhibin B, and absence of prior cryptorchidism.
Third — and the reason it is so prominent in men's-health circles — it preserves testicular function on testosterone replacement therapy (TRT): exogenous testosterone suppresses LH/FSH and collapses intratesticular testosterone (ITT), which is ~50-100× higher than serum testosterone and is required for spermatogenesis; low-dose hCG (~125-500 IU every other day) dose-dependently maintains ITT in the normal range and preserves semen parameters, allowing men to stay on TRT while protecting fertility.
This TRT-adjunct use sits on a real mechanistic and small-cohort evidence base — stronger than the analogous gonadorelin claim — though it remains largely off-label and the supporting trials are small.
The honest scope: hCG's benefits are confined to the gonadal (hypothalamic-pituitary-gonadal) axis — fertility, intratesticular testosterone, and Leydig-cell steroidogenesis.
It is NOT a longevity or healthspan drug, has no demonstrated systemic anti-aging benefit, and the once-popular 'hCG diet' for weight loss is discredited.
As a prescription gonadotropin it also carries real risks — ovarian hyperstimulation syndrome in women, gynecomastia/estradiol elevation and testicular discomfort in men — and grey-market or compounded sourcing (common in TRT and bodybuilding contexts) adds contamination, mislabeling, and dosing-accuracy concerns on top of the pharmacology.
hCG's beta-subunit mimics LH; it binds and activates the LH/CG receptor (LHCGR) on testicular Leydig cells in men and ovarian theca/granulosa cells in women — acting as a long-acting LH analogue with a far longer half-life than native LH.
Receptor activation on Leydig cells stimulates testosterone synthesis. Intratesticular testosterone (ITT) is ~50-100× higher than serum testosterone and is required for spermatogenesis; hCG sustains ITT even when pituitary LH/FSH are suppressed by exogenous testosterone.
In men, sustained Leydig-cell ITT (often with FSH) supports Sertoli-cell-driven spermatogenesis. In women, a single hCG dose mimics the mid-cycle LH surge to trigger final oocyte maturation and ovulation — provided the gonads are responsive.
How HCG (Human Chorionic Gonadotropin) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only and indication-dependent. For fertility preservation / intratesticular-testosterone maintenance on TRT, small studies used ~125-500 IU subcutaneously every other day. For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No dietary-supplement dose exists.
Can be taken without food
| Form | Type |
|---|---|
| 💊Prescription hCG — recombinant (choriogonadotropin alfa) or urinary-derived, by injection | Recommended |
| 💊Gonadorelin / pulsatile GnRH (acts upstream at the pituitary); FSH/hMG (often combined with hCG for spermatogenesis); clomiphene/enclomiphene (oral, raises endogenous LH/FSH) | Alternative |
A prescription drug, not a dietary supplement. Beware grey-market or compounded hCG marketed for TRT/bodybuilding — contamination, mislabeling, and dosing-accuracy concerns are real.
Minimum: 3 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Indication-driven, not a daily supplement: every-other-day low dosing for fertility/ITT maintenance, two-to-three-times-weekly for spermatogenesis induction, a single timed dose for the ovulation trigger. These are clinical protocols, not supplement timing.
Dose-response data unavailable. The current published research for HCG (Human Chorionic Gonadotropin) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In men whose gonadotropins are suppressed by testosterone, low-dose hCG dose-dependently keeps intratesticular testosterone in the normal range — the mechanism by which it preserves fertility on TRT.
Concomitant low-dose hCG maintained semen parameters and avoided azoospermia in small cohorts of hypogonadal men on TRT who wanted to keep fertility — an off-label but mechanism-consistent use.
In hypogonadotropic hypogonadism, hCG (alone in adult-onset/adequate-volume cases, or with FSH in congenital cases) induces testosterone production and sperm output; outcome depends on testicular volume, inhibin B, and cryptorchidism history.
A single hCG dose mimics the LH surge to trigger final oocyte maturation and ovulation in induction and IVF/IUI cycles — the established reference 'trigger'.
Driving steroidogenesis can raise estradiol (gynecomastia, water retention) in men and, in women, contributes to ovarian hyperstimulation syndrome — the main dose-related risk of fertility use.
hCG's proven effects are confined to the gonadal axis; it is not a longevity or healthspan drug, and the 'hCG diet' for weight loss is discredited.
Low-dose hCG has a real mechanistic and small-cohort basis for maintaining intratesticular testosterone and semen parameters, but it is largely off-label; discuss timing, monitoring (semen analysis, estradiol), and alternatives (e.g. sperm banking) with a reproductive endocrinologist or urologist.
An evidence-backed indication — hCG (alone or with FSH) induces spermatogenesis; congenital/Kallmann cases generally need combined hCG+FSH. Specialist-managed.
hCG is a standard trigger but carries OHSS risk; must be used with cycle monitoring under a fertility specialist.
Avoid — stimulating sex-steroid production could be harmful; specialist input required.
Avoid unverified sources — contamination, mislabeling, and inaccurate dosing are real risks; obtain prescription product through legitimate channels.
Exogenous androgens suppress LH/FSH and intratesticular testosterone; the rationale for adding hCG is to maintain Leydig-cell function and fertility. This use is real but largely off-label and supported mainly by small cohorts; it can also raise estradiol.
Frequently combined with hCG to induce spermatogenesis (men) or follicular development (women); appropriate but increases ovarian-hyperstimulation risk in women and requires monitoring.
Tip: Rotate sites; recombinant hCG tends to cause fewer local reactions than urinary product
Tip: Monitor estradiol; an aromatase inhibitor may be added under clinician guidance
Tip: Dose-related; monitor follicles by ultrasound and estradiol, and avoid/withhold the trigger in high-response cycles
Tip: Usually dose-related and reversible; adjust dose with the prescriber
Tip: Usually transient
The commonly studied dose of HCG (Human Chorionic Gonadotropin) is Prescription-only and indication-dependent. For fertility preservation / intratesticular-testosterone maintenance on TRT, small studies used ~125-500 IU subcutaneously every other day. For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No dietary-supplement dose exists.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for HCG (Human Chorionic Gonadotropin) — consistent daily use matters more than the time of day. Dosing is by indication, not a daily supplement schedule: every-other-day low doses for intratesticular-testosterone/fertility maintenance, two-to-three-times-weekly for spermatogenesis induction, and a single timed trigger dose for ovulation.
HCG (Human Chorionic Gonadotropin) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reaction (pain, redness, swelling), estradiol elevation / gynecomastia / water retention (men), ovarian hyperstimulation syndrome (women). Use caution if any of these apply to you: Hormone-sensitive tumors (e.g. prostate, breast) or other androgen/estrogen-dependent conditions; Known hypersensitivity to hCG; Use without medical supervision.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Sometimes co-prescribed to blunt the estradiol rise hCG can cause in men; alters the estrogen/androgen balance and should be clinician-managed.
These suppress endogenous gonadotropins; co-use changes the hormonal context and should only be combined under specialist protocols (e.g. assisted reproduction).